Figure 6.

Effects of different BR formulations on the relative activity of caspase-3 (A) and caspase-9 (B) in hippocampal tissue of a mouse model of AD-like Aβ neurotoxicity.

Data are expressed as the mean ± SD (n = 4). ##P < 0.01, vs. sham group; *P < 0.05, **P < 0.01, vs. model group; †P < 0.05, ††P < 0.01 (one-way analysis of variance followed by least significant difference post hoc test). AD: Alzheimer’s disease; Aβ: amyloid β-protein; BR: berberine hydrochloride; BR-S: BR solution; BR-CL: BR common nanoliposomes; BR-PL: BR PEGylated nanoliposomes; BR-Lf: BR PEGylated nanoliposomes with lactoferrin modified.